We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Trinity Biotech Gains European Approval for the Meritas® Troponin I POC Test
News

Trinity Biotech Gains European Approval for the Meritas® Troponin I POC Test

Trinity Biotech Gains European Approval for the Meritas® Troponin I POC Test
News

Trinity Biotech Gains European Approval for the Meritas® Troponin I POC Test

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Trinity Biotech Gains European Approval for the Meritas® Troponin I POC Test"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Trinity Biotech has announced that its landmark, high sensitivity Meritas® Troponin I (TnI) point-of-care (POC) test has obtained CE marking, making it the only POC product capable of meeting all the guidelines stipulated by the world’s leading cardiac organizations for the detection of heart attacks.

With CE marking achieved, the Company now intends to release the product for sale in Europe and other carefully selected markets through its specialist Cardiology Distributor network and direct selling teams.

Designed for use with the revolutionary, Meritas POC Analyzer, the Meritas Troponin I test enables fast, accurate triage and intervention for patients presenting at the emergency department with a possible myocardial infarction (MI).

Results, which are traceable to NIST SRM 2921, are comparable to those obtained using traditional top performing laboratory analyzers, and are available in just 15 minutes.

Turnaround times, patient care and outcomes are improved, helping to maximize the use of precious hospital resources and generate significant cost savings. Additional assays are currently being developed to extend the test menu further.

Advertisement